Institute for Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Institute for Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.4K	Buy	+513	New	+$28.1K	﹤0.01%	1018
2024 Q4	–	Sell	-3,175	Closed	-$223K	–	517
2024 Q3	$223K	Buy	+3,175	New	+$265K	0.03%	494

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Institute for Wealth Management's BMRN Position: Q2 2026 in Review

Institute for Wealth Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 513 shares worth $29.4K. The stake represents ﹤0.01% of the portfolio and ranks #1018 among its holdings. This is a return to the name: Institute for Wealth Management previously reported a position in BMRN as recently as Q3 2024.

Institute for Wealth Management first reported a position in BMRN in Q3 2024 and has held it in 2 quarters since. The position peaked at $223K in Q3 2024. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Institute for Wealth Management held 513 shares of BioMarin Pharmaceuticals worth $29.4K as of Q2 2026.
BioMarin Pharmaceuticals was a new Institute for Wealth Management position in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Institute for Wealth Management's portfolio in Q2 2026, its #1018 holding.
Institute for Wealth Management first reported a position in BioMarin Pharmaceuticals in Q3 2024 and has held it in 2 quarters since.
Institute for Wealth Management's BioMarin Pharmaceuticals position peaked at $223K in Q3 2024.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Institute for Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.